LifeVantage Q4 Revenue Falls 23% as Active Accounts Shrink 21%; FY27 Guidance Withheld
LFVN sits 65% above its 52-week low of $3.9 on light trading volume (0.3× avg).
Summary
LifeVantage reported Q4 FY2026 revenue of $42.4M, down 23.1% year-over-year, with diluted EPS of $0.10 versus $0.15. Full-year revenue fell 20.1% to $182.6M, active accounts dropped 21.2%, and the company withheld FY2027 guidance due to the CEO transition.
Key Events · Earnings and Guidance · LFVN
-
Q4 Revenue Down 23.1%
Fourth-quarter revenue fell to $42.4M from $55.1M a year ago, driven by lower order volume and smaller average order size across both Americas (-24.8%) and Asia/Pacific & Europe (-16.9%).
-
Full-Year Profitability Halved
FY2026 net income dropped to $5.1M ($0.40 diluted EPS) from $9.8M ($0.75) in FY2025; adjusted EBITDA fell to $13.7M from $22.1M.
-
Active Accounts Shrink 21.2%
Total active accounts fell to 104,000 from 132,000 a year ago, with active customers down 24.7% and active independent consultants down 15.7%.
-
FY2027 Guidance Withheld
Management declined to issue formal fiscal 2027 guidance, citing the recent CEO transition, leaving investors without a forward earnings anchor.
Analysis · LFVN · Life Sciences
Fourth-quarter revenue dropped 23.1% to $42.4 million, capping a fiscal year in which revenue fell 20.1% to $182.6 million and active accounts declined 21.2% to 104,000. The company withheld fiscal 2027 guidance, citing the recent CEO transition, which removes a key anchor for investors. Against that backdrop, the balance sheet remains debt-free with $14.9 million in cash, and the board still has $58.5 million remaining on its $60 million repurchase authorization — capital that could support the stock but has not stemmed the customer erosion.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LFVN was trading at $6.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $81.4M. The 52-week trading range was $3.90 to $14.28. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.